Sign up
Pharma Capital

Tissue Regenix in talks to buy US rival Cellright

There was no certainty yet that the acquisition will go ahead
picture of surgical operation
Tissue engineering is a rapidly growing business

Regenerative medicine specialist Tissue Regenix PLC (LON:TRX) has confirmed talks to buy US rival Cellright.

In a brief statement, the Leeds-based group said a temporary restraining order had been applied for by one of Cellright Technologies LLC’s members against the sale to Tissue.

Following the application Tissue Regenix confirmed discussions were underwa though it said there was no certainty yet that the acquisition will go ahead.

No other details were released.

Texas-based Cellright make a range of regenerative and graft products, notably Matrix 01 a human bone cell scaffold that is processed using the US company’s BioRinse technology. 

Tissue Regenix supplies skin, cartilages, ligaments and valves for grafts from both animals and human tissue banks that have been washed and the acellular scaffold kept intact.

PhilW.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

View All

Related Articles

scientist in a lab
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.